Haleon plc: Total Voting Rights and Capital

21 March 2024: Haleon plc ("Haleon" or the "Company) announces that the Company has today cancelled 102,272,727 ordinary shares of £0.01 each, repurchased from Pfizer Inc.

As at 21 March 2024 the total number of shares issued by Haleon plc with rights to vote is 9,132,301,104 ordinary shares of £0.01 each. There are no ordinary shares held in Treasury.

The figure of 9,132,301,104 may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

The person responsible for arranging the release of this announcement on behalf of Haleon is Amanda Mellor, Company Secretary.

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.